×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Mechanism: ALS Progression Trajectories
mechanism
2,960 words
KG: ent-dise-93f3d65f
2026-04-01
kind:mechanism
section:mechanisms
state:published
evidence:strong
Contents
ALS Progression Trajectories
⚙
Mechanism Info
Name
ALS Progression Trajectories
Summary
Comprehensive overview of ALS progression trajectories including factors, biomarkers, phenotypes, and clinical trial implications
Knowledge Graph
Related Hypotheses (7)
Cryptic Exon Silencing Restoration
Score: 0.46
Cross-Seeding Prevention Strategy
Score: 0.45
Glycine-Rich Domain Competitive Inhibition
Score: 0.43
Microglial AIM2 Inflammasome as the Primary Driver of TDP-43
Score: 0.60
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.37
Show 2 more
Related Analyses (30)
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed
What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed
How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed
What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed
What mechanisms underlie neuronal resistance to autophagy in
neurodegeneration · failed
What upstream mechanisms cause TDP-43 to trigger mPTP openin
neurodegeneration · failed
What are the neuron-specific effects of ALS-causing mutation
neurodegeneration · failed
How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed
What are the molecular signatures that distinguish protectiv
neurodegeneration · failed
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
Show 25 more
Related Experiments (30)
cGAS/STING pathway activation by TDP-43-released mtDNA
exploratory · proposed · Score: 0.95
TDP-43 mutant mouse model cGAS/STING pathway analysis
validation · proposed · Score: 0.90
TDP-43 mitochondrial invasion and mtDNA release in iPSC moto
exploratory · proposed · Score: 0.90
cGAMP biomarker analysis in ALS patient spinal cord samples
clinical · proposed · Score: 0.85
cGAMP biomarker analysis in ALS patient spinal cord samples
exploratory · proposed · Score: 0.80
s:** - Temporal analysis showing mitochondrial defects prece
falsification · proposed · Score: 0.40
Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Blood-Brain Barrier Aging and Neurodegeneration — From Leaka
validation · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
Experiment Index
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Multiscale Computational Modeling of Protein Aggregation Kin
validation · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
Show 25 more